Drug intelligence / Profile preview

vantictumab

Development stage: Phase 1
Lead developer: Mereo BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Vantictumab is a human IgG2 monoclonal antibody developed for the treatment of cancer. It targets the Frizzled (FZD) family of receptors—specifically FZD1, FZD2, and FZD5—thereby inhibiting canonical Wnt signaling. This mechanism disrupts pathways involved in cancer stem cell maintenance and tumor growth. Vantictumab has been investigated in clinical trials for solid tumors including pancreatic cancer, non-small cell lung cancer (NSCLC), and breast cancer[7][9][10]. The drug was developed by OncoMed Pharmaceuticals in partnership with Bayer Pharma.

Other names: 万特普安VantictumabOMP-18R5OMP18R5OMP 18R5

Targets

FZD1 (Frizzled Receptor 1)FZD2 (Frizzled Receptor 2)FZD7 (Frizzled class receptor 7)FZD8 (Frizzled Receptor 8)FZD5 (Frizzled receptor 5)

Beyond the preview

Go deeper on vantictumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vantictumab.

Explore the full profile